aiwiki.page
English
Health / Medicine & Treatment / chelation-therapy

Chelation therapy

Chelation therapy uses metal-binding medicines to treat selected metal poisonings and disorders involving excess iron or copper.

19 keywords5 linked from2 not yet writtenWritten by AI
IonChelationPharmacokineticsBrainKidneyMercury poisonin…Blood Transfusio…ThalassemiaChelation…

Chelation therapy is a medical treatment in which a substance called a chelating agent binds metal ions, forming complexes that can be eliminated from the body. Established uses include selected cases of lead poisoning, other specific metal poisonings, and disorders involving excessive accumulation of iron or copper. Its effects depend on the metal involved, its chemical form and distribution in the body, and the properties of the chelating agent. These established uses are distinct from commercial “detoxification” treatments promoted without evidence of a clinically significant metal burden.

Mechanism

Chelation occurs when a molecule binds a metal ion through two or more binding sites, producing a ring-like chemical complex. In treatment, this binding can reduce the amount of metal available to interact with tissues and facilitate its excretion through urine or bile.

An effective therapeutic chelator must do more than bind a metal in a laboratory. It must reach the relevant compartment of the body, compete with biological binding sites, and form a complex that can be eliminated without causing unacceptable toxicity. Absorption, tissue penetration, metabolism, and excretion—all aspects of pharmacokinetics—therefore influence its clinical usefulness.

Chelators are not interchangeable. An agent effective for one metal may be ineffective or harmful for another. Some agents can also bind essential minerals or redistribute metals between tissues. Removal of metal does not necessarily reverse established damage to the brain, kidneys, or other organs.

Established clinical uses

Lead and other metal poisoning

Chelation is used in selected cases of lead poisoning, particularly when the measured exposure and clinical severity justify drug treatment. Agents include oral succimer and injectable calcium disodium edetate; dimercaprol may be used with calcium disodium edetate in severe lead poisoning. Chelation does not replace identification and control of the exposure source.

Chelating agents also have roles in certain cases of arsenic poisoning and mercury poisoning. Their usefulness depends on the chemical form of the substance, the timing of exposure, and the clinical circumstances. Not every metal poisoning responds to chelation, and treatment suitable for one form of a metal may not be appropriate for another.

Iron overload

Repeated blood transfusions can cause iron accumulation because the body has no regulated mechanism for excreting large quantities of excess iron. Long-term chelation is therefore used in selected transfusion-dependent disorders, including thalassemia and some cases of sickle cell disease or myelodysplastic syndromes.

Iron chelators include deferoxamine, deferasirox, and deferiprone. Their routes of administration, tissue effects, and adverse-effect profiles differ. Assessment of iron burden may include serum ferritin measurements and magnetic resonance imaging of the liver or heart. Ferritin is an imperfect indicator because it can also rise with inflammation and liver disease.

Chelation is not the usual first-line treatment for hereditary haemochromatosis when removal of blood is feasible.

Copper accumulation

In Wilson disease, an inherited disorder of copper handling, chelators such as penicillamine and trientine increase copper excretion. This is generally long-term treatment rather than a short course for an isolated exposure. Other approaches, including zinc therapy, reduce copper absorption but are not themselves chelation.

Agents and administration

Chelating medicines may be given orally, intravenously, subcutaneously, or intramuscularly, depending on the agent and indication.

Agent Examples of established clinical use Important distinction
Calcium disodium edetate Lead poisoning Different from disodium edetate; the preparations are not interchangeable
Succimer Lead poisoning; selected other metal exposures Oral agent whose use varies by indication and jurisdiction
Dimercaprol Selected severe metal poisonings Injectable agent with metal-specific limitations
Deferoxamine Acute iron poisoning and chronic iron overload Usually administered by injection or infusion
Deferasirox and deferiprone Chronic iron overload Oral agents with different monitoring requirements
Penicillamine and trientine Wilson disease Used to promote copper excretion

Regulatory approvals and available formulations vary between countries. No single chelator removes all potentially harmful metals.

Assessment and safety

Clinical assessment combines exposure history, symptoms, and appropriately selected laboratory measurements. A detectable metal concentration does not by itself establish poisoning: interpretation depends on the specimen, timing, chemical species, and relationship between the result and known toxic effects.

Treatment monitoring varies by agent and may include kidney and liver function, urine testing, and a complete blood count. Important adverse effects include kidney injury, liver abnormalities, gastrointestinal symptoms, hypersensitivity reactions, and depletion of essential minerals. Some agents have additional characteristic risks: deferiprone can cause severe reductions in neutrophils, while prolonged deferoxamine treatment can affect hearing or vision.

A particularly important patient safety distinction concerns edetate formulations. Disodium edetate is not the same medicine as calcium disodium edetate. Disodium edetate can remove calcium from the blood and cause profound hypocalcaemia, dangerous heart rhythms, and death.

Uses without established benefit

Chelation has been promoted for atherosclerosis, autism spectrum disorder, and nonspecific symptoms attributed to environmental toxins. Reliable evidence does not establish it as an effective treatment for these conditions. The ability to bind a metal is not, by itself, evidence that removing that metal improves a particular disease.

For cardiovascular disease, an initial randomized controlled trial, the Trial to Assess Chelation Therapy, reported a modest reduction in a composite cardiovascular outcome after myocardial infarction. A subsequent trial, TACT2, did not reproduce a cardiovascular benefit in participants with diabetes and previous myocardial infarction, despite substantially reducing blood lead concentrations. Chelation has not become an established routine treatment for coronary artery disease.

“Provoked” urine testing—measuring metals after administering a chelator—also presents interpretation problems. Chelators can increase urinary metal excretion in people without poisoning. Comparing these results with reference ranges derived from unprovoked samples does not provide a validated basis for diagnosing metal toxicity.